Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis

Abstract

To perform a MRI monitored phase II clinical trial with a feasible sample size, using the evolution of CELs into PBHs as primary outcome parameter, a potent drug is required to obtain sufficient power.